Skip to content
By /

GLOW Research Blend: Analytical Identity, Composition, and Study Limits

An evidence-focused guide to the GLOW 70 mg research blend, its lot-specific HPLC results, component identities, measured content, and the limits of interpreting a three-peptide mixture.

GLOW research blend analytical evidence with molecular structures and HPLC chromatogram

GLOW research blend is a three-component laboratory research material containing labeled amounts of GHK-Cu, BPC-157, and TB-4. This guide explains what the current lot-specific analytical report establishes, what the individual research literature can and cannot tell investigators, and why a blended material must be evaluated as its own test article.

Research-use notice: This material is offered only for qualified laboratory, analytical, and educational research. It is not for human or veterinary use. The information below is not medical advice and does not provide directions for administration.

What the GLOW name identifies

On JD BioWorks, GLOW identifies a specific 70 mg labeled research blend: GHK-Cu 50 mg, BPC-157 10 mg, and TB-4 10 mg. The name does not establish a universal formulation across suppliers. Researchers should record the exact product, labeled composition, lot number, and certificate used in each experiment rather than treating every product called “GLOW” as interchangeable.

Current lot analytical snapshot

Field Verified report value
Product / lot GLOW 70 mg / Lot 2026-003
Certificate COA-2026-QS7JFB
Laboratory / date ILS Laboratories / September 22, 2026
Method Blend purity, identity, and quantitation by HPLC
Peptide purity 99.65% — Pass
Identity GHK-Cu, BPC-157, and TB-4 confirmed — Pass
Measured net blend content 72.51 mg
Component results GHK-Cu 52.21 mg; BPC-157 10.30 mg; TB-4 10.01 mg
Fentanyl screen Not detected — Pass

View the complete lot-specific Certificate of Analysis.

Identity, purity, and content answer different questions

Identity asks whether the analytical signals are consistent with the named components. Purity estimates the proportion of detected peptide material represented by the target peaks under the stated method. Net content estimates how much peptide material was measured. A high purity result does not replace identity or content testing, and none of these results alone establishes sterility, endotoxin level, stability after opening, or performance in a particular experimental system.

Because this is a mixture, researchers should preserve the entire report with their records. A single headline percentage cannot describe the component ratio, total content, analytical method, and scope of testing.

Research context for the individual components

GHK-Cu

GHK-Cu is a copper-binding tripeptide studied in cell-culture and animal models. A primary fibroblast study reported concentration-dependent changes in glycosaminoglycan synthesis, while a separate rat wound-chamber experiment reported changes in extracellular-matrix measures. These findings concern defined experimental systems and do not establish the behavior of this three-component blend. See the primary studies in Life Sciences and the Journal of Clinical Investigation.

BPC-157

BPC-157 has been examined largely in preclinical systems. One primary study using rat Achilles-tendon fibroblasts reported changes in growth-hormone-receptor expression and downstream cell responses under the study conditions. That experiment was conducted on isolated cells and does not validate a human use, a blended formulation, or a commercial product. See the primary tendon-fibroblast study.

TB-4

The certificate uses the identity label TB-4, referring to thymosin beta-4. Primary endothelial-cell work reported effects on directional migration in defined in-vitro and experimental assays. Those findings are specific to thymosin beta-4 and the reported models; they should not be treated as proof of a combined GHK-Cu/BPC-157/TB-4 effect. See the primary endothelial migration study.

Why a blend requires its own study design

Combining three analytes changes more than the label. A sound protocol should address the component ratio, vehicle, concentration, assay timing, controls, replicate count, detection limits, and potential analytical interference. Results from an individual component cannot be assumed to predict the mixture, and results from one blend ratio cannot automatically be generalized to another.

  • Document the lot number and COA before the material enters the workflow.
  • Use controls that can distinguish mixture effects from component-specific effects.
  • Predefine acceptance criteria and the statistical analysis plan.
  • Record handling conditions, time points, and analytical instrument parameters.
  • Avoid interpreting a chromatographic purity result as evidence of biological efficacy.

Limits of the current certificate

The current report supports the listed identity, purity, content, and fentanyl-screen results for Lot 2026-003 under the methods shown. It is lot-specific and should not be generalized to future lots. Unless a report explicitly includes a test, it should not be read as evidence for sterility, endotoxin, residual solvents, long-term stability, or suitability for any unlisted application.

Research record checklist

  • Product: GLOW 70 mg Research Blend
  • Lot: 2026-003
  • COA: COA-2026-QS7JFB
  • Labeled ratio: GHK-Cu 50 mg / BPC-157 10 mg / TB-4 10 mg
  • Independent report date: September 22, 2026
  • Study purpose, controls, endpoints, and exclusion criteria

Researchers can review the GLOW 70 mg product record for the current lot documentation and availability.

Primary sources and documentation

  1. ILS Laboratories. Certificate of Analysis COA-2026-QS7JFB, Lot 2026-003, September 22, 2026.
  2. Maquart FX, et al. Stimulation of sulfated glycosaminoglycan synthesis by GHK-Cu. Life Sciences. 1992. PMID 1522753.
  3. Maquart FX, et al. In vivo stimulation of connective tissue accumulation by GHK-Cu in rat experimental wounds. J Clin Invest. 1993. PMID 8227353.
  4. Chang CH, et al. BPC 157 and growth-hormone-receptor expression in tendon fibroblasts. Molecules. 2014. PMID 25415472.
  5. Malinda KM, et al. Thymosin beta-4 stimulates directional migration of human endothelial cells. FASEB Journal. 1997. PMID 9194528.

Last reviewed September 22, 2026. For qualified laboratory research only. Not for human or veterinary use.

Connected Materials

CONTINUE YOUR REVIEW

Next steps for qualified researchers

Use the documentation resources below, then continue directly to the catalog to review products, prices, and matching COAs.

Search Certificates of Analysis Match available analytical records to the named product, quantity, and lot. Explore Research Guides Review HPLC, LC-MS, purity, identity, storage, and traceability guidance. Browse the Research Catalog Review current products, prices, specifications, quantities, and lot-documentation status.

For qualified laboratory, analytical, educational, or institutional research only. Not for human or veterinary use.

See our reviews on Trustpilot